|
1.
|
|
Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer 2006/06
|
|
2.
|
|
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer 2007/06
|
|
3.
|
|
Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells 2007/07
|
|
4.
|
|
Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma. 2007/07
|
|
5.
|
|
Small cell carcinoma of the ovary: clinical and biological study. 2008/04
|
|
6.
|
|
Short-term serum deprivation confers sensitivity to taxanes in platinum-resistant human ovarian cancer cells. 2011/12
|
|
7.
|
|
Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy 2012/12
|
|
8.
|
|
Treatment-interval associated effect of irradiation on locoregionally-relapsed ovarian cancer. 2014/06/16
|
|
9.
|
|
Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovari 2015/03
|
|
10.
|
|
Feasibility of reduced port surgery applying Higuchi's transverse incision 2017/02
|
|
11.
|
|
MRI findings for primary fallopian tube cancer: correlation with pathological findings. 2018/02
|
|
12.
|
|
PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. 2018/03
|
|
13.
|
|
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. 2019/03
|
|
14.
|
|
Evaluation of nonhematologic toxicity in patients with cervical cancer after type III radical hysterectomy followed by concurrent chemoradiotherapy : A retrospective study 2023/04
|
|
15.
|
|
Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial. 2023/05
|
|
Display 5 items
|
|
Display all(15)
|
